Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[Analysis of the association between pre- and post-treatment genetic mutation status and treatment efficacy and survival in patients with newly diagnosed myelodysplastic syndromes with excess blasts receiving hypomethylating agent therapy].","authors":"T Zhong, T J Qin, Z F Xu, L J Pan, S Q Qu, M Jiao, Q Y Gao, Z J Xiao, B Li","doi":"10.3760/cma.j.cn121090-20241210-00553","DOIUrl":"10.3760/cma.j.cn121090-20241210-00553","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the association between pre- and post-treatment gene mutation profiles and clinical outcomes (treatment response and prognosis) in patients with myelodysplastic syndromes with excess blasts (MDS-EB) receiving hypomethylating agent (HMA) monotherapy. <b>Methods:</b> The clinical characteristics, treatment efficacy, and survival outcomes of 69 treatment-naive patients with MDS-EB who underwent next-generation sequencing (NGS) before treatment and completed at least 4 cycles of HMA monotherapy at the Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, between June 2016 and September 2023, were retrospectively analyzed. <b>Results:</b> ① The cohort comprised 47 males and 22 females with a median age of 62 years (range: 41-80). Thirty-nine patients were classified as MDS-EB1 and 30 as MDS-EB2. The median number of treatment cycles was 6 (range: 4-35). The median follow-up duration was 22 months (range: 5-72), and the median overall survival (OS) was 32 months (95% <i>CI</i>: 27-43). ② The presence of DTA (DNMT3A, TET2, or ASXL1) mutations, signaling pathway mutations, transcription factor mutations, or splicing factor mutations before HMA treatment showed no significant association with the best response within 4 treatment cycles, duration of response (DOR), or OS. TP53 mutation status was significantly associated with DOR and shorter OS. The median DOR was 3 months (95% <i>CI</i>: 1-10) for patients with biallelic TP53 mutations, 10 months (95% <i>CI</i>: 3-34) for those with monoallelic TP53 mutations, and 16 months (95% <i>CI</i>: 8-27) in patients without TP53 mutations (<i>P</i>=0.032). The median OS was 16 months (95% <i>CI</i>: 7-38), 15 months (95% <i>CI</i>: 6-40), and 35 months (95% <i>CI</i>: 14-91), respectively (<i>P</i><0.001). ③ Neither the Revised International Prognostic Scoring System (IPSS-R) nor the Molecular International Prognostic Scoring System (IPSS-M) could predict the best response within 4 treatment cycles or DOR in patients receiving HMA therapy. ④ Among patients without TP53 mutations, the median OS was 55 months (95% <i>CI</i>: 9-106) for the major clone significant clearance group (<i>n</i>=14) and 31 months (95% <i>CI</i>: 16-184) for the major clone non-significant clearance group (<i>n</i>=10) (<i>P</i>=0.013). For patients who responded to HMA treatment and had significant major clone clearance, the 3-year OS rate reached (77.8±13.9) %. <b>Conclusion:</b> For MDS-EB patients receiving HMA monotherapy, single gene mutations, IPSS-R, and IPSS-M could not effectively predict treatment outcomes before therapy. However, for patients without TP53 mutations, monitoring the degree of major clone clearance by NGS during treatment may predict the long-term efficacy in MDS patients receiving HMA therapy.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 5","pages":"417-424"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Gene therapy marks the beginning of a potential \"clinical cure\" for hemophilia B patients].","authors":"L Zhang","doi":"10.3760/cma.j.cn121090-20250304-00111","DOIUrl":"10.3760/cma.j.cn121090-20250304-00111","url":null,"abstract":"<p><p>Hemophilia B is a monogenic inherited disorder characterized by spontaneous or trauma-induced bleeding. In China, the primary treatment strategy for hemophilia B is factor Ⅸ (FⅨ) replacement therapy, requiring patients to undergo frequent venipunctures throughout their lifetime. In recent years, significant advancements have been made in gene therapy for hemophilia B. As gene therapy for hemophilia B is nearing clinical implementation in China, the Thrombosis and Hemostasis Group of the Chinese Society of Hematology of the Chinese Medical Association and the Hemophilia Treatment Center Collaborative Network of China have jointly developed the \"Chinese guidance for clinical application of Adeno-associated virus vector-based gene therapy for hemophilia B (2025)\", offering comprehensive recommendations for standardizing the entire gene therapy process. This article will introduce the background, key points, and clinical value of the guidelines to enhance awareness and emphasis on gene therapy for hemophilia B in China.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 5","pages":"385-388"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Zanubrutinib treatment of Waldenström macroglobulinemia complicated by cryoglobulinemia: a case report].","authors":"Y C Qiu, L Zhang","doi":"10.3760/cma.j.cn121090-20241105-00433","DOIUrl":"10.3760/cma.j.cn121090-20241105-00433","url":null,"abstract":"","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 5","pages":"478"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[HDAC6 inhibitor ACY-738 induces apoptosis and autophagy in diffuse large B-cell lymphoma cells through P53 acetylation].","authors":"P J Jiang, J Y Liu, G C Yang, J R Li, X L Tian, S J Yang, J Wei, X Zhang","doi":"10.3760/cma.j.cn121090-20240826-00324","DOIUrl":"10.3760/cma.j.cn121090-20240826-00324","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the anti-tumor effect of the Histone Deacetylase 6 (HDAC6) inhibitor ACY-738 and its underlying mechanisms in Diffuse Large B-cell Lymphoma (DLBCL) . <b>Methods:</b> The expression of HDAC6 in various tumors and DLBCL was analyzed using bioinformatics. DLBCL cells were treated with different concentrations of ACY-738. Cell viability, DNA synthesis, and clone formation were assessed by CCK-8 assay, EdU assay, and soft agar assay, respectively. Intracellular reactive oxygen species (ROS) levels were detected by fluorescence microscopy. Morphological changes in cells were observed using transmission electron microscopy (TEM). Mitochondrial ROS levels and apoptosis were measured by flow cytometry. The expression levels of apoptosis-related and autophagy-related proteins were detected by Western blotting. <b>Results:</b> HDAC6 was highly expressed in DLBCL (<i>P</i><0.05). ACY-738 inhibited the proliferation, DNA synthesis, and colony formation of DLBCL cells in a dose-dependent manner (<i>P</i><0.05). Treatment with ACY-738 increased intracellular and mitochondrial ROS levels in DLBCL cells in a dose-dependent manner (<i>P</i><0.05). TEM revealed that after ACY-738 treatment, mitochondria in cells were swollen and ruptured, mitochondrial cristae were reduced or absent, autolysosomes appeared, and features characteristic of apoptosis were observed. Western blotting showed that after ACY-738 treatment, the expression of the anti-apoptotic protein BCL-2 was downregulated, while the expression of Cleaved-PARP, Cleaved caspase-3, and BAX was upregulated (<i>P</i><0.05). The expression of autophagy-related proteins Atg7, Atg3, LC3B, and P62 was downregulated, and the expression of acetylated P53 protein was upregulated (<i>P</i><0.05) . <b>Conclusion:</b> The HDAC6 inhibitor ACY-738 induces mitochondria-dependent apoptosis and autophagy in DLBCL cells by acetylating P53, thereby inhibiting DLBCL cell proliferation.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 5","pages":"437-444"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese guidance for the clinical application of Adeno-associated virus vector-based gene therapy for hemophilia B (2025)].","authors":"","doi":"10.3760/cma.j.cn121090-20250304-00110","DOIUrl":"10.3760/cma.j.cn121090-20250304-00110","url":null,"abstract":"<p><p>The mainstay of treatment for hemophilia B is Factor Ⅸ or non-factor drug therapy; however, as the disease is incurable, lifelong treatment is required. In recent years, gene therapy for hemophilia B has advanced significantly, with three adeno-associated virus (AAV) vector-based gene therapy products receiving market authorization globally. Among these, Palbociclib was recently approved in China. AAV vector gene therapy is characterized by its irreversible post-treatment effects and potential for long-term efficacy; however, suboptimal efficacy or loss of efficacy has been observed in some cases during early clinical trials. Eligibility for AAV vector gene therapy primarily depends on several factors, including patient diagnostic subtype, age, inhibitor status, AAV capsid antibody titer, and the preferences of the patient and/or their family. Given that AAV vector-based gene therapy for hemophilia has become an accessible frontier treatment, the Thrombosis and Hemostasis Group of the Chinese Society of Hematology, Chinese Medical Association, and the Hemophilia Treatment Center Collaborative Network of China have jointly formulated this guidance. This guidance aims to standardize operational procedures and follow-up recommendations, ensuring that patients receive standardized management when undergoing this novel therapeutic approach.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 5","pages":"410-416"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Develop and assessment of a predictive model for the first-course efficacy of acute myeloid leukemia].","authors":"F Zhu, Y L Zhou, Y Zhang, L P Mao, D Zhou, L Y Ma, C M Yang, W J Yu, X N Ye, J Y Wei, H T Meng, M Yang, W Y Mai, J J Qian, Y L Ren, Y J Lou, J Huang, G X Xu, W Z Xie, H Y Tong, H F Wang, J Jin","doi":"10.3760/cma.j.cn121090-20240816-00305","DOIUrl":"10.3760/cma.j.cn121090-20240816-00305","url":null,"abstract":"<p><p><b>Objective:</b> To identify the relevant factors for the first-course remission of acute myeloid leukemia (AML) and to develop a predictive model as well as assess its predictive capability. <b>Methods:</b> Clinical data of 749 patients newly diagnosed with AML admitted to the Department of Hematology, the First Affiliated Hospital, Zhejiang University, School of Medicine from January 1, 2019, to April 30, 2023, were collected and randomly divided into training and validation sets. Multivariate logistic regression analysis was conducted to determine variables associated with complete remission in the first course of induction therapy, and a predictive model was established based on these variables. The receiver operating characteristic (ROC) curve of the predictive model was plotted, and the area under the curve (AUC) was calculated. <b>Results:</b> The indicators predicting the first remission course included peripheral blood white blood cell count during onset, CBF::MYH11 fusion gene, CEBPA bZIP region mutation, myelodysplastic syndrome-related gene mutation, and induction chemotherapy regimen selection as independent factors for the first remission course. The model's area under the training and validation curves was 0.738 (95% <i>CI</i>: 0.696-0.780) and 0.726 (95% <i>CI</i>: 0.650-0.801), respectively. The Hosmer-Lemeshow test results yielded <i>P</i>-values of 0.993 and 0.335, respectively. <b>Conclusion:</b> In this study, the developed model demonstrates a strong predictive capability for the efficacy of the first course of patients with AML, providing valuable guidance to clinicians in assessing patient prognosis and selecting appropriate treatment strategies.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"336-342"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application of the variant allele frequency of myeloid-associated gene mutations in myelodysplastic syndrome].","authors":"M Y Shang, L Su","doi":"10.3760/cma.j.cn121090-20240806-00293","DOIUrl":"10.3760/cma.j.cn121090-20240806-00293","url":null,"abstract":"<p><p>Myelodysplastic syndrome (MDS) is a heterogeneous clonal myeloid malignancy with a variable prognosis. Some myeloid-related gene alterations have been found to be associated with the diagnosis and prognosis of MDS. As a result, multiple myeloid-related gene mutations have been added to International Working Group for Prognosis in MDS (IWG-PM) and other MDS prognosis evaluation systems as diagnostic and prognostic indications. Further research using the variable allele frequency (VAF) detection technique demonstrated that myeloid-related genes evolve dynamically during the course of MDS with some regularity. Furthermore, significant relevance have been found between the VAF evolution of particular myeloid-related genes and MDS subtypes, risk classification, and prognosis. This article provides an overview of the application of VAF of myeloid-related gene mutations in MDS research, highlighting the critical role of gene mutation VAF in MDS subtype categorization, risk stratification, and therapy response assessment.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"372-376"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety of zanubrutinib in treating refractory/relapsed warm autoimmune hemolytic anemia].","authors":"S P Shen, C Yang, M Chen, B Han","doi":"10.3760/cma.j.cn121090-20241110-00442","DOIUrl":"10.3760/cma.j.cn121090-20241110-00442","url":null,"abstract":"<p><p>This retrospective analysis included 10 patients with relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) who received zanubrutinib (treatment course: 3-6 months) and completed at least 3 months of follow-up at Peking Union Medical College Hospital from July 2022 to January 2024. The cohort included two male and eight female patients with a median age of 63 years (range: 36-76), who had received a median of 9 months (range: 3-22) of previous therapies. At 1-month, 3-month, and final follow-up (median 7 months), the overall response (OR) rates were 30%, 60%, and 60%, with corresponding complete response (CR) rates of 20%, 40%, and 40%, respectively. The median time to achieve a response was 2 months (range: 1-2) among the responders. No disease relapse or clonal progression was documented during follow-up. Treatment-related adverse events occurred in 30% of the patients (all grade 1-2 reversible events). One responder died of infectious multiple organ failure at 8 months after treatment initiation. Our results indicate that zanubrutinib provides rapid amelioration of anemia with manageable short-term safety in patients with relapsed/refractory wAIHA.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"355-358"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on the diagnosis and treatment of plasmablastic lymphoma (2025)].","authors":"","doi":"10.3760/cma.j.cn121090-20241213-00566","DOIUrl":"10.3760/cma.j.cn121090-20241213-00566","url":null,"abstract":"<p><p>Plasmablastic lymphoma (PBL) originates from activated B cells in the terminal differentiation stage of the germinal centers. PBL is characterized by unique clinical, pathological, and molecular features, demonstrating high aggressiveness and poor prognosis. It exhibits a low incidence and a challenging diagnosis, with a lack of standardized treatment protocols. To improve the understanding of PBL among clinical physicians in China and enhance diagnostic and treatment levels, which will facilitate the initiation of multicenter clinical research, the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and the Lymphoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO) have organized relevant experts to formulate this consensus.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"295-301"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparison of the efficacy of continuous VA chemotherapy and I/HDAC consolidation in postremission therapy for acute myeloid leukemia fit for standard chemotherapy].","authors":"L Sun, P P Zhang, S M Ren, N Zhou, L Y Li, Z Z Wang, W G Cui, F Yang, J M Luo, L Yang","doi":"10.3760/cma.j.cn121090-20240529-00198","DOIUrl":"10.3760/cma.j.cn121090-20240529-00198","url":null,"abstract":"<p><p><b>Objective:</b> To compare the efficacy and safety of continuous venetoclax combined azacitidine (VA) chemotherapy and intermedium/high-dose cytarabine (I/HDAC) consolidation in patients with acute myeloid leukemia (AML) fit for standard chemotherapy (transform from UNFIT) . <b>Methods:</b> Clinical data of patients who were fit for standard chemotherapy were collected among those with AML who underwent VA induction in the Department of Hematology, the Second Hospital of Hebei Medical University. The overall survival (OS), relapse-free survival (RFS), event-free survival (EFS), and incidence of adverse events were analyzed retrospectively. <b>Results:</b> This study enrolled 69 patients, consisting of 46 cases in the VA group and 23 cases in the I/HDAC group. We revealed the following. ① The median OS, RFS, EFS were 26.18, 24.69, 20.34 months in the VA group, and 34.14, 30.99, 28.42 months in the I/HDAC group, respectively, with no statistically significant difference (all <i>P</i>>0.05). Median OS of patients who underwent I/HDAC consolidation with European Leukemia Net (ELN) favorable-risk, positive measurable residual disease (MRD), wild type FLT3, or IDH1/2 mutation was significantly longer than those who received VA (<i>P</i><0.05). ②Adverse events rate of grade 3 - 4 neutropenia, grade 3 - 4 thrombocytopenia, and bacteremia were significantly lower in the VA group than in the I/HDAC group (<i>P</i><0.05) . <b>Conclusions:</b> I/HDAC consolidation was more likely to help get survival benefits for patients with ELN favorable-risk, positive MRD, wild type FLT3, or IDH1/2 mutation. Continuous VA chemotherapy exhibited superior safety than I/HDAC consolidation.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 4","pages":"343-348"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}